z-logo
Premium
Genetic lesions of the TRAF 3 and MAP 3K14 genes in classical H odgkin lymphoma
Author(s) -
Otto Claudia,
Giefing Maciej,
Massow Anne,
Vater Inga,
Gesk Stefan,
Schlesner Matthias,
Richter Julia,
Klapper Wolfram,
Hansmann MartinLeo,
Siebert Reiner,
Küppers Ralf
Publication year - 2012
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2012.09113.x
Subject(s) - gene , lymphoma , biology , genetics , immunology
Summary Hodgkin and Reed/Sternberg (HRS) cells in classical H odgkin lymphoma ( cHL ) show constitutive activation of nuclear factor ( NF )‐κB. Several genetic lesions contribute to this deregulated NF ‐κB activity. Here, we analysed two further NF ‐κB regulators for genetic lesions, the inhibitory factor TRAF 3 and the key signalling component of the alternative NF ‐κB pathway, MAP 3K14 ( NIK ). Single nucleotide polymorphism ( SNP ) array analysis of c HL cell lines revealed a uniparental disomy of the long arm of chromosome 14 associated with a biallelic deletion of TRAF 3 located on this chromosome in cell line U‐HO1. Cloning of the deletion breakpoint showed a 123 371 bp deletion. No inactivating mutations of TRAF 3 were found in six other c HL cell lines or in microdissected HRS cells from seven cHL . However, in primary c HL samples interphase cytogenetic analyses revealed signal patterns indicating monoallelic deletion of TRAF 3 in 3/20 other cases. SNP array analysis revealed a gain of copy number for MAP 3K14 in three c HL cell lines. Gains of MAP 3K14 were detected in 5/16 cases of primary cHL . In conclusion, in rare instances, HRS cells harbour inactivating mutations of the TRAF 3 gene and recurrently show gains of MAP 3K14 , indicating that more components of NF ‐κB signalling show genetic lesions in HRS cells than previously known.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here